ATARA Biotherapeutics, Inc. ATA129-EBV-302: Multicenter, Open Label, Phase 3 study of Tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-associated post-transplant lymphoproliferative disease after failure of Rituximab or Rituximab and Chemotherapy (ALLELE study),
Role: Investigator,
Atara Biotherapeutics, Inc.,
(12/2024 - 12/2025)
Status: Approved
Internal
Investigator initiated: Conventional prophylactic regimen of oral dexamethasone versus short-course intravenous dexamethasone in preventing paclitaxel-related hypersensitivity reactions in breast and gynecologic-oncology patients: A prospective, randomized, open-label study,
Role: Investigator,
LLU Dept. of Gynecology & Obstetrics,
(02/2024 - 01/2025)
Status: Completed
Predictors of hypomagnesemia with denosumab in patients with metastatic bone disease from solid malignancies: A single-institution retrospective study,
Role: Investigator,
LLU Dept. of Pharmacy Practice,
(11/2023)
Status: Approved
Bicalutamide plus leuprolide versus degarelix plus leuprolide as androgen deprivation therapy for patients with advanced or metastatic prostate cancer: A retrospective cohort study assessing incidence of tumor flare and cost-differences between each regimen,
Role: Investigator,
LLU Dept. of Pharmacy Practice,
(11/2022 - 01/2024)
Status: Completed
Investigator Initiated: A Retrospective chart review of patients treated with immune checkpoint inhibitors (ICI) to evaluate severe and fatal adverse events in the emergency department,
Role: PI,
LLU Dept. of Pharmacy Practice,
(07/2021 - 10/2024)
Status: Completed
Investigator Initiated: The bone-targeting agents and the need for electrolyte monitoring in cancer patients: A retrospective cohort study of cancer patients treated between January 1,2014 to June 24, 2020,
Role: PI,
LLU Dept. of Pharmacy Practice,
(07/2020 - 09/2024)
Status: Completed
Prevention of Taxol hypersensitivity reactions: Oral dexamethasone given night before and morning of Taxol infusion versus short-course intravenous dexamethasone infusion given 30 minutes prior to Taxol infusion (retrospective review),
Role: PI,
LLU Dept. of Pharmacy Practice,
(09/2016 - 09/2017)
Status: Completed
Medication reconciliation in an ambulatory cancer center --impact of the oncology pharmacist,
Role: PI,
LLU Dept. of Pharmacy Practice,
(07/2016 - 07/2017)
Status: Completed
Safety and efficacy of pegfilgrastim when given less than 14-days before next chemotherapy cycle: a retrospective review of 14 days regimens containing 5-fluorouracil continuous infusions,
Role: PI,
LLU Dept. of Pharmacy Practice,
(07/2016 - 07/2017)
Status: Completed
Lymphocytosis in patients receiving outpatient interleukin-2 therapy,
Role: Investigator,
LLU Cancer Institute,
(11/2011 - 11/2012)
Status: Completed
Risk Factors of Hypomagnesemia in Patients with Bone Metastases from Solid Malignancies Treated with Zoledronic Acid: A Single-institution Retrospective Study,
Role: PI,
LLU Dept. of Pharmacy Practice,
(10/2024)
Status: Approved
Cost analysis of subcutaneous daratumumab compared to intravenous daratumumab in multiple myeloma patients: A retrospective chart review,
Role: PI,
LLU Dept. of Pharmacy Practice,
(11/2024)
Status: Approved